Plné znění - 454/2009 Sb.

Nařízení vlády

§1  §2  §3  §4

Příloha č. 1 - Látky s anabolickým a jiným hormonálním účinkem

Příloha č. 2 - Metody s dopingovým účinkem

INFORMACE

454

XXXXXXXX XXXXX

xx xxx 7. prosince 2009,

kterým xx xxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxx, xx se xxxxxxxx xx látky x xxxxxxxxxxx x xxxxx xxxxxxxxxxx xxxxxxx x xxxx je jejich xxxxx xxxxxxxx, x xx se xxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xx xxxxxx xxxxxxxxxxx ve zvyšování xxxxxxx kyslíku v xxxxxxx xxxxxxxxx x xx jiné metody x xxxxxxxxxx xxxxxxx
&xxxx;

Xxxxx xxxxxxxx xxxxx §289 xxxx. 4 xxxxxx x. 40/2009 Xx., xxxxxxx zákoník:

§1

Xx látky x xxxxxxxxxxx x xxxxx xxxxxxxxxxx xxxxxxx xx xxxxxx §288 trestního xxxxxxxx xx xxxxxxxx xxxxx, xxxxx jsou xxxxxxx v příloze č. 1 x tomuto xxxxxxxx.

§2

Xxxxxx xxxxxxxxx xx x látek x xxxxxxxxxxx x jiným xxxxxxxxxxx xxxxxxx xx xxxxxx §288 xxxxxxxxx xxxxxxxx rozumí xxxx xxx jeden xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx nedělitelné xxxxxx xxxx xxxxxxxxxxxx tyto xxxxx nebo xxxxxxx xxxxxxxx xxxxxx xxxxx xx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx.

§3

Xx xxxxxx xxxxxxxxxxx xx zvyšování xxxxxxx xxxxxxx x xxxxxxx xxxxxxxxx x za xxxx metody x xxxxxxxxxx xxxxxxx xx xxxxxx §288 xxxxxxxxx xxxxxxxx se xxxxxxxx xxxxxx, xxxxx jsou xxxxxxx v příloze č. 2 x tomuto nařízení.

§4

Xxxx nařízení xxxxxx xxxxxxxxx dnem 1. xxxxx 2010.

Xxxxxxxx xxxxx:

Xxx. Xxxxxxx, XXx. x. x.

Xxxxxxxxxx xxxxxxxxxxxxx:

XXXx. Xxxxxxxx x. x.

Xxxxxxx x. 1 x nařízení xxxxx x. 454/2009 Xx.

Xxxxx x anabolickým x xxxxx hormonálním xxxxxxx

X. XXXXXXXXXX XXXXX

X.1 Xxxxxxxxxx xxxxxxxxxx xxxxxxxx (XXX)

x) xxxxxxxx AAS

1. 1-androstendiol (5x-xxxxxxx-1-xx-3x,17x-xxxx);

2. 1-androstendion (5x-xxxxxxx-1-xx-3,17-xxxx);

3. 1-xxxxxxxxxxx (17x-xxxxxxx-5x-xxxxxxx-1-xx-3-xx);

4. 4-xxxxxxxxxxxxxxxxxx (4,17x-xxxxxxxxxxxxxxxx-4-xx-3-xx);

5. 19-norandrostendion (xxxx-4-xx-3,17-xxxx);

6. xxxxxxxxx (19-xxxxxxxxxxxxxxxx);

7. xxxxxxxxxx;

8. xxxxxxxx;

9. xxxxxxx (androsta-1,4-dien-3,17-dion);

10. xxxxxxx (17x-xxxxxxx-17x-xxxxxxxxxxxxxx-4-xxx [2,3-d] xxxxxxxx);

11. dehydrochlormethyltestosteron (4-chloro-17b-hydroxy-17a-methylandrosta-1,4-dien-3on);

12. xxxxxxxxxxxxxxxxxxxxxxx (17x-xxxxxx-5x-xxxxxxx-2-xx-17x-xx);

13. xxxxxxxxxxx;

14. xxxxx-4,9-xxxx-3,17-xxxx (19-norandrosta-4,9-dien-3,17-dion);

15. ethylestrenol (19-xxx-17x-xxxxx-4-xx-17-xx);

16. xxxxxxxxxxxxxx;

17. xxxxxxxxxx;

18. xxxxxxxxx (17x-xxxxxxx-17x-xxxxxx-5x-xxxxxxxxxx [2,3-x]-xxxxxxx);

19. xxxxxxxxx;

20. kalusteron;

21. klostebol;

22. xxxxxxxxxx;

23. xxxxxxxxxx;

24. xxxxxxxxxxx (17x-xxxxxxx-17x-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

25. xxxxxxxxxxx;

26. xxxxxxxxxxx (2x, 17x-xxxxxxxx-5x-xxxxxxxxx-3-xx-17x-xx);

27. xxxxxxxxx;

28. xxxxxx-1-xxxxxxxxxxx (17x-xxxxxxx-17x-xxxxxx-5x-xxxxxxx-x-xx-3-xx);

29. xxxxxxxxxxxxxx (17x-xxxxxxx-17x-xxxxxxxxxxx-4,9-xxxx-3-xx);

30. methylnortestosteron (17x-xxxxxxx-17x-xxxxxxxxxx-4-xx-3-xx);

31. xxxxxxxxxxxxxxxxx;

32. xxxxxxxxxxxxxxx (17x-xxxxxxx-17x-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

33. xxxxxxxxx;

34. xxxxxxxxx;

35. xxxxxxxxxx;

36. xxxxxxxxxxxx;

37. xxxxxxxxxxxxxx;

38. xxxxxxxx;

39. xxxxxxxxxx;

40. xxxxxxxxxxx;

41. oxymetholon;

42. xxxxxxxxxxx ([3,2-c]pyrazol-5a-etioallocholan-17b-tetrahydropyranol);

43. xxxxxxxxx;

44. xxxxxxxxxx;

45. xxxxxxxxx;

46. tetrahydrogestrinon (18x-xxxx-xxxxxx-4,9,11-xxxxx-17x-xx-3-xx);

47. xxxxxxxxx;

48. xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx;

x) xxxxxxxxx XXX

1. 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3x, 17b-diol);

2. 5-androstendion (xxxxxxx-5-xx-3, 17-xxxx);

3. 19-xxxxxxxxxxxxxx;

4. 19-xxxxxxxxxxxxxxxxx;

5. 3a-hydroxy-5a-androstan-17-on;

6. 3x-xxxxxxx-5x-xxxxxxxxx-17-xx;

7. 5x-xxxxxxxxx-3x, 17x-xxxx;

8. 5x-xxxxxxxxx-3x, 17x-xxxx;

9. 5x-xxxxxxxxx-3x, 17a-diol;

10. 5x-xxxxxxxxx-3x, 17b-diol;

11. androst-4-en-3a, 17x-xxxx;

12. xxxxxxx-4-xx-3x, 17b-diol;

13. xxxxxxx-5-xx-3x, 17x-xxxx;

14. xxxxxxx-5-xx-3x, 17x-xxxx;

15. androst-5-en-3b, 17x-xxxx;

16. xxxxxxxxxxxxx (xxxxxxx-5-xx-3x, 17x-xxxx);

17. xxxxxxxxxxxxx (xxxxxxx-4-xx-3, 17-xxxx);

18. xxxxxxxxxxxxxxxxxx;

19. xxx-xxxxxxxxxxxxxxxxxx;

20. xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx XXXX);

21. xxxxxxxxxxx;

22. xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.

X.2 Ostatní xxxxxxxxxx xxxxx

1. xxxxxxxxxxx;

2. selektivní xxxxxxxxxx androgenových receptorů (XXXX), xxxxxxxxx:

2.1 xxxxxxxxx (XXX-40233);

3. xxxxxxx;

4. zeranol;

5. xxxxxxxxxx;

6. xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.

B. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

X.1 Xxxxx stimulující xxxxxxxxxxx

x) xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx:

1. darbepoetiny (xXXX);

2. xxxxxxxxxxxxx (XXX);

3. xxxxxxxxxx založené xx XXX, xxxxxxxxx:

3.1 EPO-Fc;

3.2 xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (CERA);

4. XXX-xxxxxxxxx xxxxxxxxxx x xxxxxx sloučeniny, xxxxxxxxx:

4.1 XXXX 530;

4.2 xxxxxxxxxxx;

x) xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxx:

1. daprodustat (XXX1278863);

2. XXX2 xxxxxxxxxx (XXX 85-3934);

3. roxadustat (XX-4592);

4. xxxxxxxxxx (AKB-6548);

c) xxxxxxxxxx XXXX, xxxxxxxxx: 1. X-11706;

x) xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX - β), xxxxxxxxx:

1. xxxxxxxxxxxx;

2. xxxxxxxxxxx.

X.2 Xxxxxxxxx xxxxxxx x xxxxxx uvolňující xxxxxxx

x) xxxxxxxxxxxxxxxxxx (XX) x xxxxxxxxxxxx xxxxxx (XX) x xxxxxx xxxxxxxxxx xxxxxxx

1. xxxxxxxxx;

2. xxxxxxxxxx;

3. xxxxxxxxxxx;

4. xxxxxxxxx;

5. xxxxxxxxxxx;

6. nafarelin;

7. xxxxxxxxxxx;

x) xxxxxxxxxxxxxx, xxxxxx xxxxxxxxxx xxxxxxx;

x) xxxxxxx hormon (XX), jeho xxxxxxxxx x xxxxxxxxxx faktory

1. xxxxxxxxx xxxxxxxxx xxxxxxx, xxxxxxxxx:

1.1 XXX-9604;

1.2 xXX 176-191;

2. hormon uvolňující xxxxxxx hormon (XXXX) x xxxx xxxxxxx, xxxxxxxxx:

2.1 XXX-1293;

2.2 XXX-1295;

2.3 XXX-1295 XXX;

2.4 dumorelin;

2.5 xxxxxxxxxx;

2.6 xxxxxxxxxx;

2.7 xxxxxxxxxxx;

2.8 xxxxxxxxxxx;

x) sekretagogy xxxxxxxxx xxxxxxx (XXX) x xxxxxxxx ghrelinového xxxxxxxxx, xxxxxxxxx:

1. anamorelin;

2. xxxxxxxxxx (XX-677);

3. xxxxxxxxxx (NNC 26-0161);

4. xxxxxxxxxxx (ghrelin);

5. xxxxxxxxxxx;

6. tabimorelin;

e) uvolňující xxxxxxx xxxxxxxxx xxxxxxx XX (GHRP), xxxxxxxxx:

1. xxxxxxxxxxxx;

2. examorelin (xxxxxxxxx);

3. XXXX-1;

4. XXXX-2 (xxxxxxxxxxx);

5. XXXX-3;

6. XXXX-4;

7. XXXX-5;

8. XXXX-6;

x) další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx účinky.

B.3 Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx

x) xxxxxxxxxxxxx xxxxxxx faktory (XXX);

x) xxxxxxxxxxxx xxxxxxx xxxxxx (XXX);

x) xxxxxxxx xxxxxxx xxxxxxx faktor-1 (IGF-1) x xxxx xxxxxxx;

x) xxxxxxxxxx růstové xxxxxxx (XXX);

x) xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX);

x) xxxxxxxx-β4 x xxxx deriváty, xxxxxxxxx:

1. TB-500;

g) xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX);

x) xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X. HORMONOVÉ X XXXXXXXXXXX XXXXXXXXXX

X.1 Xxxxxxxxxx xxxxxxxx

1. xxxxxxxxxxxxxxxx;

2. anastrozol;

3. xxxxxxxxx;

4. xxxxxxxxx;

5. xxxxxxxx;

6. xxxxxxxxxxx;

7. další látky x podobnou chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.

C.2 Xxxxxxxxxx xxxxxxxxxx estrogenových xxxxxxxxx (XXXX)

1. xxxxxxxxx;

2. xxxxxxxxx;

3. xxxxxxxxx;

4. xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

C.3 Xxxxxxx xxxxxxxxxxxxxx látky

1. cyklofenil;

2. xxxxxxxxxxx;

3. xxxxxxxx;

4. další xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X.4 Xxxxx modifikující funkce xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx

X.5 Metabolické xxxxxxxxxx

x) xxxxxxxxxx XXX-xxxxxxxxxx proteinkinázy (XXXX), xxxxxxxxx:

1. XXXXX;

x) xxxxxxxx receptoru δ xxxxxxxxxxxx peroxizomovými xxxxxxxxxxxxx (XXXXδ), xxxxxxxxx:

1. cardarin (XX1516, XX501516, xxxxxxxxx);

x) xxxxxxxx x mimetika xxxxxxxx;

x) xxxxxxxxx;

x) agonisté Xxx-XxxX, xxxxxxxxx:

1. Xxxxxxxxxx (XX9009);

x) xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

C.6 Xxxxxxxxxx xxxxxxxxxxx hormony

a) xxxxxxxxxx xxxxxxx α-XXX, xxxxxxxxx:

1. xxxxxxxxxxxx;

2. xxxxxxxxx X (xxxxxxxxxxxx);

3. xxxxxxxxx XX;

x) xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxx x. 2 x xxxxxxxx vlády x. 454/2009 Xx.

Xxxxxx x xxxxxxxxxx xxxxxxx

X. XXXXXXXXX XXXXXXX XXXXXXX

1. Xxxxxx xxxxxx xxxxxx xxxxx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx xxxxxxx x xxx podobných xxxxxxxx xxxxxxxxxxx xxxxxx.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx produkty (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13) a xxxxx produkty x xxxxxxxx xxxxxxx.

X. GENOVÝ XXXXXX

1. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx s xxxxxxxxxxx xxxxxx xxxxxxxxx výkon.

2. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx xxxx xxxxxxx xxxx mechanismy xxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxx, umlčování xxxx x xxxxxxxxxxx xxxxxxx xxxx.

Xxxxxx xxxxxxx x. 454/2009 Xx. nabyl xxxxxxxxx dnem 1.1.2010.

Xx xxxxx xxxxxx xxxxxxxx xxxxxxxx jsou xxxxxxxxxx xxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx předpisem x.:

2/2012 Xx., xxxxxx xx xxxx xxxxxxxx xxxxx x. 454/2009 Xx., xxxxxx xx xxx účely xxxxxxxxx xxxxxxxx stanoví, xx xx xxxxxxxx xx xxxxx s xxxxxxxxxxx x xxxxx xxxxxxxxxxx xxxxxxx x jaké xx xxxxxx větší xxxxxxxx, x co xx xxx xxxxx xxxxxxxxx xxxxxxxx považuje xx metodu xxxxxxxxxxx xx xxxxxxxxx xxxxxxx xxxxxxx v xxxxxxx xxxxxxxxx a xx xxxx xxxxxx x xxxxxxxxxx účinkem

s xxxxxxxxx xx 5.1.2012

359/2021 Sb., xxxxxx se mění xxxxxxxx xxxxx x. 454/2009 Xx., xxxxxx xx pro xxxxx xxxxxxxxx xxxxxxxx xxxxxxx, xx xx xxxxxxxx xx látky x xxxxxxxxxxx a jiným xxxxxxxxxxx xxxxxxx a xxxx xx xxxxxx xxxxx xxxxxxxx, x xx se xxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx za metodu xxxxxxxxxxx ve xxxxxxxxx xxxxxxx xxxxxxx x xxxxxxx xxxxxxxxx x xx xxxx xxxxxx x xxxxxxxxxx účinkem, xx znění nařízení xxxxx x. 2/2012 Xx.

x xxxxxxxxx xx 1.1.2022

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx v xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx jich xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx právního xxxxxxxx.